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Abstract: Non-small cell lung carcinoma (NSCLC) is one of the
leading causes of death from cancer in both Eastern and Western
countries. For patients with stage I NSCLC, full lobar or more
extensive surgical resection is the treatment of choice. However,
even among patients with surgically resected, stage I NSCLC, up to
30% of patients die of the disease within 5 years. At present, apart
from clinical stage, there are no established cancer-specific clinical
variables or biomarkers that reliably identify individuals at increased
risk of death after surgical resection—individuals who could be
candidates for adjuvant therapy or alternative management strate-
gies. At a recent international workshop, participants discussed a
clinical trial to compare radiation therapy with surgery among
patients with stage I NSCLC. This study offers the opportunity to
prospectively obtain, bank, and analyze tissue and other clinical
specimens, which should facilitate the identification of new biomar-
kers for early detection, prognosis, and therapy in lung cancer.
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Non-small cell lung carcinoma (NSCLC) is one of theleading causes of death from cancer in both Eastern and
Western countries.1,2 The number of patients diagnosed with
NSCLC is expected to increase significantly over the next
few decades because of widespread screening for early de-
tection.
For patients with stage I NSCLC (TNM categories
T1N0M0 and T2N0M0),3 full lobar or more extensive surgi-
cal resection is the treatment of choice and produces 5-year
survival rates of 60% to 80%.4,5 However, for some patients
with tobacco-related illness (e.g., chronic obstructive pulmo-
nary disease), severe cardiovascular disease, or other medical
conditions, surgical resection is not feasible because it in-
volves excessive risk. An alternative to surgery is available:
several series have documented the efficacy and safety of
stereotactic body radiation therapy (SBRT) in the treatment
of stage I NSCLC.6–9 SBRT can be offered not only to
medically inoperable patients but also to patients who refuse
surgery.
In February 2006, the International Association for the
Study of Lung Cancer (IASLC) hosted a workshop during
which experts addressed several issues relating to protocol
design for a potential international clinical trial comparing the
results of surgery and SBRT among patients with stage I
NSCLC. In addition to having great clinical importance, such
a trial represents a unique opportunity to investigate the
molecular pathogenesis of lung cancer and to study the utility
of known and novel molecular markers in predicting response
to radiation therapy and in predicting recurrence and survival.
In this review, we briefly discuss the current knowledge regard-
ing the molecular pathology and prognostic markers for early
NSCLC and offer a proposal for tissue banking strategies to
facilitate the identification of new NSCLC biomarkers.
PATHOLOGY OF NSCLC AND ITS PRECURSOR
LESIONS
From histopathologic and biological perspectives, lung
cancer is a highly complex neoplasm.10 More than 99% of
lung cancers are carcinomas. However, within that broad
category exist several histological subtypes, including small
cell lung carcinoma (SCLC; 20% of lung cancers) and the
NSCLC subtypes squamous cell carcinoma (30%); adenocar-
cinoma, including the noninvasive subtype bronchioloalveo-
lar carcinoma (40%); and large cell carcinoma (9%).11 The
frequency of lung cancer histological subtypes has shifted in
the past decades: adenocarcinoma has surpassed squamous
cell carcinoma as the most common type of lung cancer, and
the incidence of SCLC is steadily decreasing.
The pathologic diagnosis of lung cancer is confirmed
by examination of cytologic or surgical pathology specimens.
The location of the tumor and the condition of the patient may
influence the type of specimen that is obtained. Histological
specimens can be obtained by bronchoscopic or needle bi-
opsy (fine-needle aspiration or core biopsy) or by an open
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biopsy procedure, such as thoracoscopy, excisional wedge
biopsy, lobectomy, or pneumonectomy.
As with other epithelial malignancies, lung cancers are
believed to arise from preneoplastic or precursor lesions in
the respiratory mucosa.12–14 Although the sequential changes
leading to such preneoplastic lesions have been well defined
for centrally arising squamous lung carcinomas, they have
been poorly documented for large cell lung carcinomas, lung
adenocarcinomas, and SCLCs.12,13 The 2004 World Health
Organization (WHO) and International Association for the
Study of Lung Cancer (IASLC) histological classification of
preinvasive lesions of the lung lists two main morphologic
forms of preneoplastic lesions for NSCLC11: (1) squamous
dysplasia and carcinoma in situ (CIS) and (2) atypical adeno-
matous hyperplasia (AAH). Current information suggests that
preneoplastic lung lesions are frequently extensive and mul-
tifocal throughout the respiratory epithelium, indicating a
field effect in which much of the respiratory epithelium has
been mutagenized, presumably from exposure to tobacco-
related carcinogens.15,16 This phenomenon is called field
cancerization.16
Squamous Cell Carcinoma
Mucosal changes in the large airways that may precede
the development of invasive squamous cell carcinoma in-
clude squamous dysplasia and CIS.12,13 Mucosal changes in
the large airways that may precede or accompany invasive
squamous cell carcinoma include hyperplasia, squamous
metaplasia, squamous dysplasia, and CIS.12,13 Little is known
about the rate of progression of squamous dysplasia to CIS
and ultimately to invasive squamous cell carcinoma.
Adenocarcinoma
A subset of adenocarcinomas may be preceded by
morphological changes including AAH in peripheral airway
cells.12,17 AAH is a discrete parenchymal lesion arising in the
alveoli close to terminal and respiratory bronchioles. Because
AAH lesions are small, they are usually incidental histolog-
ical findings; however, they may be detected grossly, espe-
cially if they are 0.5 cm or larger. AAH is characterized by an
alveolar structure lined by rounded, cuboidal, or low colum-
nar cells. The postulated progression of AAH to adenocarci-
noma with bronchioloalveolar features, apparent from the
increasingly atypical morphology, is supported by morpho-
metric, cytofluorometric, and molecular studies.13,17 Distinc-
tion between highly atypical AAH and nonmucinous bron-
chioloalveolar adenocarcinoma is sometimes difficult.
MOLECULAR PATHOGENESIS OF NSCLC
Tobacco smoking habit is responsible for approxi-
mately 90% of all cases of NSCLC.10 Carcinogenic effects of
tobacco smoking include the induction of enzymes and the
formation of covalent DNA adducts, which may result in
DNA misreplication and mutation. Most NSCLCs are diag-
nosed among former smokers, suggesting that accumulation
of molecular damage during exposure to cigarette smoke sets
in progress a cascade of events that leads to cancer develop-
ment decades after smoking cessation.10 The current knowl-
edge regarding the early pathogenesis of NSCLC is summa-
rized in Figure 1.
The genetic and molecular changes involved in the
carcinogenesis of epithelial tumors, including those of the
FIGURE 1. Summary of current knowledge regarding NSCLC pathogenesis. The sequence of pathologic and molecular
change involved in the pathogenesis of lung cancer is better known for squamous cell carcinoma histology (left side of the
panel). The molecular changes include chromosomal deletions, genetic instability, activation of inflammation-related mole-
cules, cell proliferation, oncogenes mutation (e.g., KRAS and BRAF ), and inactivation of tumor suppressor genes (e.g., P16 and
TP53). For lung adenocarcinoma (right side of the panel), at least two molecular pathways have been identified, smoking
(KRAS) and nonsmoking (EGFR and HER2/NEU)-related pathways. Although EGFR mutations have been detected in normal re-
spiratory epithelium, HER2/NEU mutations have not been studied at early stages of lung adenocarcinoma development.
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lung, are notably diverse and complex; however, they can be
systematically reviewed using Hanahan and Weinberg’s hall-
marks of cancer as a guide.18 These hallmarks include growth
signaling self-sufficiency, insensitivity to antigrowth signals,
ability to evade apoptosis, limitless replicative potential,
capability to sustain angiogenesis, and tissue invasion and
metastasis. NSCLC subtypes, including squamous cell carci-
noma and adenocarcinoma, share many of these hallmarks of
cancer; however, the subtypes also may be differentiated
from each other on the basis of specific molecular abnormal-
ities.19 Of interest, many of these molecular abnormalities are
being examined as prognostic markers and potential targets
for novel molecularly targeted therapies.
Growth Signaling Self-Sufficiency
Many growth factors and their receptors are abnormally
expressed by lung cancer cells and adjacent stromal cells,
producing autocrine and paracrine growth stimulation
loops.10 Several growth factors and receptors are encoded by
proto-oncogenes that become activated by various mecha-
nisms during the development of lung cancer.10 One such
proto-oncogene is RAS, part of an important signal transduc-
tion pathway. Point mutation of the KRAS gene is detected in
15% to 20% of all NSCLCs and approximately 30% of lung
adenocarcinomas, with mutation at codon 12 being the most
frequent.10 KRAS mutations are frequently associated with
tobacco smoking.
Two tyrosine kinase growth factor receptors, EGFR
and Her2/Neu, are often overexpressed in NSCLC.20 Re-
cently, somatic mutations of EGFR and HER2/NEU have
been reported in patients with lung adenocarcinoma who
were never-smokers or light smokers, female, and of East
Asian ethnicity.21–28 EGFR mutations are clinically relevant
because most of them have been associated with sensitivity of
lung adenocarcinoma to small-molecule tyrosine kinase in-
hibitors (gefitinib and erlotinib).21–23,29 EGFR mutations have
been detected in up to 40% of lung adenocarcinomas and only
in 3% of other NSCLC histologies.30 More than 80% of the
mutations detected in EGFR among patients with lung cancer
are in-frame deletions in exon 19 or a single missense
mutation in exon 21 (L858R).21–27 It has been proposed that
lung cancer cells with mutant EGFR might become physio-
logically dependent on the continued activity of the gene for
the maintenance of their malignant phenotype, leading to
accelerated development of lung adenocarcinoma.31 Recent
studies have demonstrated that high EGFR copy number in
tumor cells, identified by fluorescence in situ hybridization
(FISH), may be a predictor of response to EGFR tyrosine
kinase inhibitors and be involved in the pathogenesis of lung
adenocarcinoma.32–34
Patients can develop resistance to tyrosine kinase in-
hibitors, and such acquired resistance can be preceded by the
appearance of new mutations. Two independent groups stud-
ied patients with NSCLC who experienced a relapse after
remission with EGFR tyrosine kinase inhibitors and found
that every patient had a novel mutation in EGFR—a point
mutation resulting in the substitution of a methionine for a
threonine residue at position 790 (T790M) in exon 20.35,36 In
vitro studies demonstrated that this mutation caused resis-
tance.35,36 Interestingly, this novel EGFR mutation has
been detected in some primary tumors and in NCI-H1975
NSCLC cells not treated with EGFR tyrosine kinase in-
hibitors. Recently, it has been shown that most NSCLC
cell lines with mutant EGFR, including those with the
mutation conferring resistance to tyrosine kinase inhibitors
(T790M), exhibit characteristics consistent with a radio-
sensitive phenotype, including delayed DNA repair kinet-
ics, defective ionizing radiation-induced arrest in DNA
synthesis or mitosis, and pronounced increases in apopto-
sis or micronuclei.37
Her2/Neu is highly expressed in approximately 30% of
NSCLCs, mainly adenocarcinomas, and is associated with a
shorter survival time and multiple drug resistance.38–40 Re-
cently, HER2/NEU mutations have been identified in lung
cancers, but they are less common than EGFR mutations.28,41
Of interest, Shigematsu et al. demonstrated that HER2/NEU
mutations (overall frequency in NSCLC 1.6%) were signifi-
cantly more frequent among never-smokers (3.2%) and pa-
tients with adenocarcinomas (2.8%). Activating mutations of
BRAF and PIK3CA, two key players in kinase pathway
activation, have also been identified in NSCLC—in 3% and
1% of tumors, respectively. These mutations may also iden-
tify subsets of tumors sensitive to targeted therapy.42,43
Thus, at least two different molecular pathways have
been identified in the pathogenesis of lung adenocarcinoma—
smoking-associated activation of KRAS signaling and non-
smoking-associated activation of EGFR and Her2/Neu sig-
naling (Figure 1).
Insensitivity to Antigrowth Signals
Tumor suppressor genes play a critical role in control-
ling normal cell growth. They generally inhibit tumorigenesis
but can also be involved in the response to and repair of DNA
damage. According to Knudson’s hypothesis,44 loss of func-
tion of tumor suppressor genes requires that both alleles be
inactivated. One allele is inactivated by mutation, methyl-
ation (epigenetic) changes, or other changes that target the
individual gene, whereas the other allele is usually inacti-
vated as part of loss of many genetic markers by deletion,
nonreciprocal translocation, or mitotic recombination in the
chromosomal region—a phenomenon referred to as allele
loss or loss of heterozygosity. Studies of loss of heterozygos-
ity as a marker of inactivation of tumor suppressor genes have
shown that a number of chromosomal regions are lost in lung
cancer cells, including 1q, 3p, 4p, 4q, 5q, 6p, 6q, 8p, 8q, 9p
(P16 locus), 9q, 10p, 10q, 11p, 13q (retinoblastoma [RB]
locus), 14q, 17p (TP53 locus), 18q, 19p, and 22q.45–48 Sev-
eral distinct regions of loss in 3p have been identified by
high-density allelotyping, including 3p25–26, 3p24, 3p21.3–22
(several sites), 3p14.2, and 3p12, suggesting that there are
several different tumor suppressor genes located on 3p. The
3p21.3 region has been extensively examined for putative tumor
suppressor genes. Several candidate tumor suppressor genes
have been identified in 3p,49 including FHIT at the 3p14.2
region50,51; RASSF1A,52,53 SEMA3B,54,55 and FUS156–59 at
3p21.3; and DUTT1/ROBO1 and retinoic acid receptor (RAR),
located at 3p12 and 3p22-24, respectively.60,61
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Other chromosomal regions affected by allelic loss in
lung cancer encompass known tumor suppressor genes, in-
cluding TP53 (17p13), RB (13q12), P16 (9p21), and PTEN
(10q22), and these genes are often found to be abnormal in
lung cancer.18 The TP53 gene encodes a protein that func-
tions as a transcription factor that can detect and bind sites of
primary DNA damage. Chromosome 17p13 sequences, the
site of the TP53 locus, are frequently hemizygously lost in
NSCLC (65%),62 and mutational inactivation of the remain-
ing allele occurs in 50% to 75% of these neoplasms.63 The
p16/RB pathway regulates the G1 to S phase transition in the
cell cycle. In most NSCLCs, this pathway is disrupted by
cyclin D1, CDK4, and P16 abnormalities are common (P16
abnormalities are seen in 30% to 50% of cases).45
Aberrant methylation of normally unmethylated CpG-
rich areas (“CpG islands”) that are located in or near the
promoter region of many genes has been associated with the
inactivation of tumor suppressor genes in human cancer,
including lung cancer.64,65 Several genes are frequently meth-
ylated in primary NSCLCs, including adenomatous polyposis
coli(APC), RAR-, CDH13 (H-cadherin), FHIT, RASSF1A,
SEMA3B, PTEN, tissue inhibitor of metalloproteinase-3,
P16, death-associated protein kinase, p14ARF, GSTP1, Rep-
rimo, Wingless-type inhibitory factor-1, Caveolin-1, high in
normal-1, laminin-5-encoding genes, and target of methyla-
tion-induced silencing.66–76 The number of genes discovered
to have a high incidence of abnormal methylation in lung
cancer is rapidly increasing. All these recent findings suggest
that aberrant gene methylation is a frequent abnormality in
lung cancers and may be exploited for risk assessment,
diagnosis, and development of novel therapeutic approaches.
Apoptosis Evasion
Tumor cells often escape the normal physiological
response (termed programmed cell death or apoptosis) when
challenged by cellular and DNA damage. Key players in
apoptosis evasion include the TP53 gene and the BCL2
proto-oncogene.10 There are two main pathways that mediate
apoptosis: (1) the death receptor pathway (tumor necrosis
factor, Fas ligand, or TRAIL receptors), which activates
caspase-8 and caspase-10; and (2) the mitochondrial path-
way, which activates caspase-9. p53 activates Bcl-2, which
inhibits apoptosis by the mitochondrial pathway. Lung tumor
cells overexpress Bcl-2 to overcome apoptotic signals from
Myc and Ras expression. Immunohistochemical studies have
shown that Bcl-2 protein is expressed frequently in
NSCLC.77,78
Limitless Replication
The limitless replicate potential of cancer cells is ac-
quired during tumor development. The ends of human chro-
mosomes (telomeres) contain hexameric TTAGGG tandem
repeats.79 During normal cell division, the absence of telom-
erase activity is associated with progressive telomere short-
ening, leading to cell senescence and normal cell mortality.79
Germ cells, some stem cells, and most cancer cells have
telomerase activity, which results in replacement of those
hexameric repeats during cell division and can lead to cellular
immortality.79 Most NSCLCs (80%) show high levels of
telomerase activity, which is associated with increased cell
proliferation rates and advanced stage at diagnosis.80,81
Sustained Angiogenesis Pathway
Nutrients and oxygen supplied by the vasculature are
crucial for cell survival; therefore, angiogenesis is critical for
tumor growth. Angiogenesis involves interactions among
tumor cells, endothelial cells, and stromal cells.82 Growth
factors and cytokines have been implicated in angiogenesis;
so too have proteases that break down the extracellular
matrix.
A number of angiogenic factors, including inducers and
inhibitors regulating endothelial cell proliferation and migra-
tion, have been identified in lung cancer. Vascular endothelial
growth factor (VEGF), also known as vascular permeability
factor, is a key regulator of angiogenesis.83 High VEGF
expression, reported in approximately 60% of stage I
NSCLCs, is closely associated with high intratumoral angio-
genesis and poor prognosis.84 In NSCLC, most studies sup-
port a correlation between high VEGF expression, high
microvessel density (MVD), and poor prognosis.82 Other
angiogenic factors recently studied in lung cancer include
platelet-derived growth factor and its receptor,85 basic fibro-
blast growth factor and its receptors 1 and 2,86 ephrins,87 and
hypoxic inducible factor-1.88
Invasion and Metastasis Pathway
Lung cancer development and growth, subsequent tis-
sue invasion, and metastasis are the products of mutation,
deletion, methylation, and other processes previously dis-
cussed. Evolution of malignant tumors involves invasion of
adjacent tissues and distant metastasis; during these pro-
cesses, several junctional complexes and extracellular matrix
proteins are altered by tumor.89 Integrins, cadherins, and
selectins are families of adhesion or junctional molecules
with different genetic and biochemical properties. In lung
cancer, basement membrane fragmentation, the resulting pro-
liferations of stromal elements, and cancer cell invasion have
been attributed by some to often-reduced laminin  chains
(3 and 5). A study demonstrated frequent loss of gene
expression and epigenetic inactivation of the LN5-encoding
genes LAMA3, LAMB3, and LAMC2 in lung cancers and
frequent (20% to 60%) loss of expression of these genes in
NSCLC cell lines.71 In addition, methylation was relatively
frequent in NSCLC tumors (22% to 47%), and at least one
gene was methylated in 47% of NSCLC tumors.71 However,
epithelial to mesenchymal transition of tumor cells, by which
they undergo a developmental switch from a polarized epi-
thelial phenotype to a motile mesenchymal phenotype, plays
an important role in tumor invasion and metastasis. Epithelial
to mesenchymal transition has been described among many
types of cancer, including lung cancer.90
MOLECULAR PROFILING STUDIES IN NSCLC
There is a belief that the pathogenesis and behavior of
individual lung cancers cannot be completely understood
through the analysis of individual genes or a small number of
genes.10 Recently, the use of molecular global profiling tech-
nologies, including cDNA microarrays and proteomics-based
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analyses, has led to a significant number of exciting new
biological discoveries and important correlations between
gene and protein expression patterns and disease states in
lung cancer.91 In lung cancer, cDNA microarray analyses
have been used to simultaneously investigate thousands of
RNA expression levels and begin to identify patterns associ-
ated with biological and phenotypical characteristics.92,93 Oli-
gonucleotide and cDNA microarrays can contain probes rep-
resenting more than 30,000 genes. Supervised learning
methods have been applied successfully to distinguish among
classes of cancer, and unsupervised learning methods have
been applied to discover new classes of genes.
A variety of studies on gene expression profiles have
sought to identify new molecular markers for different
histological subtypes of lung cancer, including adenocar-
cinoma.92,93 Recently, two studies have demonstrated the
potential clinical applications of gene expression profiling
in early lung cancer—one predicted the risk of disease recur-
rence94 and the other predicted response to commonly used
cytotoxic agents.95 Recently, an 11-gene expression signature
associated with “stem cell-ness” was found to separate pa-
tients with different cancers, including lung cancer, into
good- and poor-prognosis groups; however, this stem cell-
associated signature has not been validated or further studied
in NSCLC.96
Recently, it has been suggested that proteomics-based
approaches complement the genomics initiatives and repre-
sent the next step in attempts to understand the biology of
cancer. As mRNA expression is not always correlated with
levels of protein expression, cDNA-based gene expression
analysis cannot always indicate which proteins are expressed
or how their activity might be modulated after translation.97
Accordingly, comprehensive analysis of protein expression
patterns in tissues might improve our ability to understand the
molecular complexities of tumor cells. Among other meth-
ods, matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS) can be used to profile
proteins in tissues.98 This technology can not only address
peptides and proteins in sections of tumor tissues but can also
be used for high-resolution imaging of individual biomol-
ecules present in tissue sections.98 Proteomic pattern analysis
using MALDI-TOF MS on small amounts of frozen NSCLC
tissues has been used to accurately classify and predict
histological groups and nodal involvement and patient sur-
vival.91 If these data are confirmed in larger series, the results
could have great prognostic and therapeutic implications for
patients with NSCLC. Recently, selective profiling of pro-
teins has been successfully performed from fine-needle aspi-
rates by MALDI-TOF MS in lung cancer.99
Tissue microarrays are used to simultaneously study the
expression of proteins in hundreds of tissue samples. Tissue
microarrays offer a time- and cost-effective means of screen-
ing large tissue banks for biomarker expression or simulta-
neously examining serial sections obtained from the same
tumor specimen.100 Combined with automated new image
analysis systems, tissue microarrays are molecular profiling
tools that offer simultaneous analysis with in situ methods
(immunohistochemistry, fluorescent and non-fluorescent in
situ DNA and RNA hybridizations) of all tumors in one
experiment under highly standardized conditions.100 Tissue
microarrays are considered important tools for validating data
obtained from high-throughput molecular profiling studies.
PROGNOSTIC MARKERS IN NSCLC
Clinical and pathologic stages according to the TNM
system are still the most powerful predictors of overall
survival among patients with NSCLC.3 Overall survival dif-
FIGURE 2. Proposed schema of
tissue and blood specimen collec-
tion and banking for a potential in-
ternational randomized clinical trial
comparing surgical resection versus
stereotactic body radiation therapy
among patients with stage I non-
small cell lung cancer. Tissue 1, di-
agnostic specimen. Tissue 2, surgi-
cally resected sample. Tissue 3,
sample at recurrence (local or me-
tastasis). Blood 1, baseline. Blood 2,
at stereotactic body radiation ther-
apy response assessment. Blood 3,
at recurrence or 3-year follow-up
visit.
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fers among patients with surgically resectable NSCLC (stages
I to IIIA), suggesting the existence of other prognostic pa-
rameters in addition to stage. During the past decade, a
number of molecular prognostic markers have been exten-
sively studied in early NSCLC.101,102 However, most of these
studies were retrospective, the studies used different method-
ologies for molecular marker assessments, only a small sub-
set of the studies included multivariate analyses, and the
results regarding the prognostic value of most of the markers
studied were conflicting and are still a matter of debate.
Zhu et al.102 reviewed one decade of publications on
NSCLC molecular prognostic markers and identified 17 im-
munohistochemistry markers investigated by eight or more
groups. The results were not consistent for any of the mark-
ers. EGFR, Her2/Neu, Ki-67, p53, and Bcl-2 immunohisto-
chemical overexpression has been studied exhaustively, and
the last three markers have been suggested to be relevant but
weak prognostic markers in early NSCLCs.102 In addition, six
other markers—overexpression of cyclin-E and VEGF-A and
loss of expression of p16, p27, -catenin, and E-cadherin—
are considered promising candidate prognostic markers, cor-
relating with poor prognosis in 50% or more of the studies
reported.102 Other molecular prognostic markers, including
genetic and epigenetic (gene promoter methylation) changes,
have been reported in lung cancer; however, they have not
been validated in independent studies.72,101
Molecular profiling studies may be very helpful for
classifying tumors and identifying patients with early NSCLCs
with worse prognosis who would benefit from adjuvant ther-
apies. A rigorous prospective approach, using training and
testing cohorts, to study molecular prognostic markers in lung
cancers could improve our chances of identifying true mo-
lecular prognostic markers that may be reliably applied to
clinical practice.
PROPOSAL FOR TISSUE BANKING AND
MOLECULAR RESEARCH QUESTIONS FOR
CLINICAL TRIALS IN EARLY-STAGE NSCLC
Although the main end points of the proposed interna-
tional cooperative clinical trial comparing surgery and SBRT
in stage I NSCLC will be overall and disease-specific sur-
vival, the trial also gives us a unique opportunity to prospec-
tively study and identify biological markers to predict re-
sponse to SBRT and, most importantly, to molecularly
classify tumors from different geographic areas around the
world to gain a better understanding of the early pathogenesis
of lung cancer and the factors predictive of recurrence and
survival in surgically treated patients. Using molecular pro-
filing strategies and analysis of specific pathways or markers
in tumor or blood specimens, an attempt could be made to
molecularly classify early NSCLCs and determine the mo-
lecular characteristics identifying patients with the greatest
potential benefit from adjuvant treatment based on chemo-
therapeutic or targeted agents.
Potential research goals may include, among others, the
following (1): identify molecular tissue and blood (e.g.,
genetic polymorphism and serum proteomic) markers predic-
tive of survival, recurrence, and metastasis development in
patients with NSCLC; (2) establish characteristics of precur-
sor lesions and the field cancerization phenomenon in
NSCLC pathogenesis by smoking status, gender, and, very
importantly, ethnic background; (3) identify molecular tissue
and blood markers to predict response to and survival benefit
from SBRT; (4) identify molecular markers predictive of
response to chemotherapeutic or targeted therapeutic agents
at time of recurrence.
Therefore, development of a tissue and blood (serum,
plasma, and circulating cells) bank with specimens obtained
in this trial, including detailed prospectively collected clinical
data, is of the utmost importance. An international consor-
tium of pathologists will be necessary to perform tissue bank
activities and consensual histopathologic processing and
evaluation and to establish criteria for sample distribution to
perform biomarker analysis. The preliminary design of this
trial indicates that there are several opportunities to collect
and bank tissue. Specimens are schematically represented in
Figure 2.
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